B Braun withdraws dura mater product
This article was originally published in Clinica
German healthcare company B Braun Melsungen has voluntarily withdrawn all Lyodura dura mater implants worldwide, produced before January 1996, because it cannot trace the origin of all products. An inability to trace raw material in all cases contravenes good manufacturing practice standards, admitted head of marketing Gerhard Meil. He claimed that the origin of most tissue used in Lyodura can be traced.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.